- Home
- EDU vs ROIV Comparison
EDU vs ROIV Comparison
Compare EDU & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDU | ROIV |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | China | United Kingdom |
| Employees | N/A | 721 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 28.7B |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDU | ROIV |
|---|---|---|
| Price | $55.69 | $40.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $62.80 | $28.94 |
| AVG Volume (30 Days) | 521.1K | ★ 8.2M |
| Earning Date | 04-22-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | $12.83 | N/A |
| Revenue Next Year | $11.16 | $744.61 |
| P/E Ratio | $24.75 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.25 | $14.50 |
| 52 Week High | $64.97 | $42.50 |
Technical Indicators
Market Signals| Indicator | EDU | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 63.02 |
| Support Level | $53.81 | $33.15 |
| Resistance Level | $59.78 | $42.50 |
| Average True Range (ATR) | 1.10 | 1.46 |
| MACD | -0.41 | 0.20 |
| Stochastic Oscillator | 23.39 | 75.14 |
Price Performance
Historical ComparisonAbout EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in livestreaming e-commerce.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.